Dr. Keri Renee Maher, DO

Dr. Maher practices at VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia.

Dr. Maher's NPI, 1407134471, was assigned on July 25, 2011. Dr. Maher holds Virginia license 0102206147.

Dr. Maher's primary practice is VCU Medical Center, at 1250 East Marshall Street, Richmond, VA 23298 in Richmond City. The practice phone is (804) 828-9000.

Dr. Maher's primary practice is VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia. Dr. Maher is also affiliated with VCU Health Tappahannock Hospital. The medical group on file is MCV Physicians. Dmand AI also links Dr. Maher to 1 more group practice or clinic and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maher practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Maher's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Maher's licenses on file in 2 states: Virginia and Arizona.

CMS data shows 778 Medicare services from Dr. Maher across 10 procedure codes in 2024, for 138 Medicare patients. Medicare paid $57,345 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 138 Medicare patients who saw Dr. Maher in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 2.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maher's median patient age at 68, with 47% women.

In 2024, Dr. Maher wrote 751 Medicare Part D claims for 78 patients. 70% of them were for generic drugs. CMS names the drug for 566 of them, across 17 drugs with 11 or more claims each, at $1,189,876 in total drug cost. In 2023, CMS named 376 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Maher for performance year 2024, reported as part of a group. Dr. Maher accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 13 papers to Dr. Maher, published from 2019 to 2025. 2023 was the busiest year, with 4. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Azacitidine. Dr. Maher has published most often in EJHaem. Dr. Maher's most frequent co-authors are Ian Bouligny, MD, Tilak Rajendrakumar Patel, MD and Andrew M. Yeager, MD.

Dmand AI links Dr. Maher to 10 clinical trials, 3 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Burkitt Lymphoma, Epstein-Barr Virus Infections and Myelodysplastic Syndromes. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 88 general payments to Dr. Maher from 18 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 88% of the total. Sobi, Inc paid the most, $88,901.